Paula Toth-Russell, MD
Neurology · Mishawaka, INNPI 1588756712
Payments from drug & device makers
Across 747 payments — averaging $106.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$34K
- EMD Serono, Inc.$20K
- Sanofi$6K
- AbbVie$5K
- Livanova USA, Inc.$4K
- Biogen$2K
- plus $9K from 54 others
What the payments were for
- Consulting fees$7,73910%
- Speaking & faculty fees$52,78966%
- Travel & lodging$3,6245%
- Food & beverage$15,18719%
- Education$1690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$22,219
- Mavenclad$18,218
- AUSTEDO$10,538
- AUBAGIO$5,595
- BOTOX$3,750
- Vumerity$1,526
- VNS - Sentiva$1,500
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$1,500
- Rebif$245
- VNS Therapy$235
- Fycompa$125
- XCOPRI$125
- NURTEC ODT$117
- MAYZENT$114
- Infinity DBS Pulse Generators$105
How this compares
$79,508 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 90 | $913,329 |
| FirdapseAmifampridine Phosphate | 12 | $591,534 |
| CopaxoneGlatiramer Acetate | 33 | $266,401 |
| VumerityDiroximel Fumarate | 29 | $250,070 |
| EpidiolexCannabidiol (Cbd) | 13 | $137,143 |
| Glatiramer Acetate | 56 | $131,388 |
| Avonex (4 Pack)Interferon Beta-1a | 11 | $88,400 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $87,724 |
| Nurtec OdtRimegepant Sulfate | 59 | $85,158 |
| QuliptaAtogepant | 40 | $79,089 |
| RytaryCarbidopa/Levodopa | 57 | $72,491 |
| VimpatLacosamide | 38 | $61,053 |
| FycompaPerampanel | 45 | $58,310 |
| NuplazidPimavanserin Tartrate | 12 | $50,956 |
| LamictalLamotrigine | 29 | $48,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Catalyst Pharmaceuticals, Inc.Firdapse | $565 | $591,53412 claims |
| BiogenVumerity, Avonex (4 Pack) | $2,388 | $338,47040 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $33,623 | $266,40133 claims |
| UCB, Inc.Vimpat, Briviact, Neupro | $455 | $111,77470 claims |
| AbbVieQulipta, Ubrelvy | $5,239 | $100,61751 claims |
| PfizerNurtec Odt, Eliquis | $264 | $98,45970 claims |
| Amneal Pharmaceuticals LLCRytary | $246 | $72,49157 claims |
| Eisai Inc.Fycompa | $260 | $58,31045 claims |
| Acadia Pharmaceuticals IncNuplazid | $40 | $50,95612 claims |
| SK Life Science, Inc.Xcopri | $344 | $39,14830 claims |
| Neurelis, Inc.Valtoco | $93 | $36,13329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.
Other neurology in Mishawaka
- Anitha RaoMishawaka$165K
- Francisco Gomez-DossiMishawaka$68K
- Michael EnglertMishawaka$50K
- Kevin KristlMishawaka$35K
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Martin FarlowIndianapolis$4.8M
- Jared BroschIndianapolis$4.7M
- Ajay GuptaFort Wayne$2.5M
- Christopher WilsonAvon$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.